Try our mobile app

Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting

Published: 2021-04-20 11:45:00 ET
<<<  go to JAZZ company page

Xywav demonstrated statistically significant differences in change in Epworth Sleepiness Scale score (p-value